<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2091-3-16.anc" start="32866" end="32871" sStart="32767" offset="99" sid="r7.1.use.v.0507" wn="1" wnkey="use%2:34:01::" text="Agonists and antagonists were dissolved in extracellular solution and delivered to cells using a rapid perfusion system (Warner Instruments, Hamden, CT)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-3-16.anc" start="32075" end="32086" sStart="null" offset="0" sid="null" wn="2" wnkey="transfer%2:40:01::" text="Transfected tsA201 cells were &lt;b&gt;transferred&lt;/b&gt; to a recording chamber and submerged in extracellular recording buffer containing 25 mM HEPES pH 7.4, 140 mM NaCl, 1.7 mM MgCl 2 , 5 mM KCl, 1.8 mM CaCl 2 . Patch electrodes (2-2." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2091-3-16.anc" start="2214" end="2223" sStart="null" offset="174" sid="r8.suggest.v.0600" wn="3" wnkey="suggest%2:32:02::" text="Antagonists to 5-HT 3 Rs are clinically efficacious in the treatment of chemotherapy-induced emesis [ 15 ] and recent studies on human subjects have suggested their potential application in the treatment of early onset alcoholism [ 16 17 ] ." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2091-3-16.anc" start="9226" end="9232" sStart="null" offset="206" sid="r11.severe.j.0229" wn="1" wnkey="severe%5:00:00:intense:00" text="For W89F and W89Y, the changes in K i observed for lerisetron were much smaller than for the alanine mutations at Y142A and Y152A, as would be expected for the less severe nature of these mutations." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2091-3-16.anc" start="8047" end="8053" sStart="null" offset="125" sid="r11.severe.j.0228" wn="2147483646" wnkey="null" text="For W89, an alanine substitution has been shown to prevent binding of [ 3H]granisetron; therefore a less severe mutation was constructed." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-3-16.anc" start="31354" end="31359" sStart="null" offset="0" sid="null" wn="2" wnkey="rapid%5:00:02:fast:01" text="Binding was terminated by &lt;b&gt;rapid&lt;/b&gt; filtration onto a GF/B filters." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-3-16.anc" start="31354" end="31359" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Binding was terminated by &lt;b&gt;rapid&lt;/b&gt; filtration onto a GF/B filters." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-3-16.anc" start="31354" end="31359" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Binding was terminated by &lt;b&gt;rapid&lt;/b&gt; filtration onto a GF/B filters." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-3-16.anc" start="31354" end="31359" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Binding was terminated by &lt;b&gt;rapid&lt;/b&gt; filtration onto a GF/B filters." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-3-16.anc" start="31354" end="31359" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Binding was terminated by &lt;b&gt;rapid&lt;/b&gt; filtration onto a GF/B filters." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-3-16.anc" start="31354" end="31359" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Binding was terminated by &lt;b&gt;rapid&lt;/b&gt; filtration onto a GF/B filters." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-3-16.anc" start="32884" end="32889" sStart="null" offset="0" sid="null" wn="2147483644" wnkey="null" text="Agonists and antagonists were dissolved in extracellular solution and delivered to cells using a &lt;b&gt;rapid&lt;/b&gt; perfusion system (Warner Instruments, Hamden, CT)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-3-16.anc" start="31354" end="31359" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Binding was terminated by &lt;b&gt;rapid&lt;/b&gt; filtration onto a GF/B filters." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-3-16.anc" start="31354" end="31359" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Binding was terminated by &lt;b&gt;rapid&lt;/b&gt; filtration onto a GF/B filters." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-3-16.anc" start="31354" end="31359" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Binding was terminated by &lt;b&gt;rapid&lt;/b&gt; filtration onto a GF/B filters." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2091-3-16.anc" start="26867" end="26877" sStart="null" offset="172" sid="r10.particular.j.0522" wn="3" wnkey="particular%5:00:00:uncommon:00" text="The model for lerisetron binding will be further refined as its interactions with other binding site amino acids are investigated [ 26 32 33 ] . Of particular interest would be potential interactions of the N-benzyl group that would account for the decrease in binding affinity of analog 2. Additional information gained from comparison of our model with the recent crystal structure of the AChBP demonstrates that lerisetron can be roughly 'fit' into the binding site such that all the residues line up as shown in our model." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2091-3-16.anc" start="27431" end="27436" sStart="null" offset="137" sid="r9.paper.n.0948" wn="5" wnkey="paper%1:10:02::" text="While this is not direct evidence that the model is correct, subsequent molecular modeling of the data presented in this paper may provide further support for our hypothesis." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2091-3-16.anc" start="18802" end="18806" sStart="null" offset="0" sid="null" wn="1" wnkey="lose%2:40:02::" text="The Y142A mutation produced a 160 fold change in K i . This change reflects the binding energy &lt;b&gt;lost&lt;/b&gt; as a result of the alanine substitution." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2091-3-16.anc" start="35697" end="35701" sStart="null" offset="97" sid="r8.life.n.0891" wn="2147483645" wnkey="null" text="D-MEM, Penicillin-Streptomycin, fetal bovine serum, and Trypsin were obtained from New Life Technologies." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2091-3-16.anc" start="19104" end="19108" sStart="null" offset="256" sid="null" wn="2147483645" wnkey="null" text="The observed change in Ki on wt receptors is much larger than that observed for removal of the N-benzyl group (31 fold), but is similar to that observed for substitution of the distal amino nitrogen in analog 2 (400 fold)." />
  </sentences>
</list>